The latest: Koolearn Technology Holding Ltd. (1797.HK) said it will stop offering after-school tutoring services for kindergartners to ninth-year students (K-9) for academic subjects included in China’s compulsory education system. The Hong Kong-listed online arm of education giant New Oriental (EDU.US) said the cessation will take place by the end of November, according to a statement released after markets closed on Monday.

Looking Up: The move, a response to China’s ban on such classes by for-profit companies, will remove a huge overhang for Koolearn, allowing the education services provider to move forward on a more solid footing. China’s after-school tutoring services sector has been in a state of turmoil since new rules recently took effect aimed at easing pressure on students from after-school coursework.

Take Note: Classes being discontinued accounted for between 58% and 73% of the company’s K-12 education services business over the company’s last two fiscal years through May 2021, Koolearn estimated. K-12 services generated 787 million yuan ($123 million), or more than half of Koolearn’s total revenue of 1.4 billion yuan in its latest fiscal year.

Digging Deeper: The roughly dozen publicly-listed Chinese companies offering after-school tutoring services have lost most of their value since the start of the year, with some stocks down 90% or more. Koolearn is one of the first companies to announce how it will move ahead under the new restrictions. Based on its latest announcement, the discontinued business should result in a reduction of 32% to 40% of its current revenues.

Market Reaction: Koolearn shares were down 2.8% at HK$4.88 late on Tuesday, giving the company a market value of HK$4.9 million ($630 million). The shares are down about 80% this year, but have stabilized at their current level since early August as more details of the new restrictions emerged.

To subscribe to Bamboo Works free weekly newsletter, click here   

Recent Articles

The loss-making developer of cancer immunotherapies raised just enough financing last year to cross the valuation threshold for a Hong Kong listing.

Sunho Biologics gets green light for downsized IPO

The loss-making developer of cancer immunotherapies raised just enough financing last year to cross the valuation threshold for a Hong Kong listing Key Takeaways: Sunho Biologics has no revenue or…